Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Says Q3 Revenue Jumps 43 Percent as Loss Narrows; Firm Ups '06 Guidance

NEW YORK (GenomeWeb News) — Sequenom today said third-quarter revenues increased 43 percent as R&D spending rose 16 percent and losses decreased by 16 percent.
Total receipts for the three months ended Sept. 30 increased to $6.5 million from $4.6 million year over year.
R&D spending increased to $3 million from $2.6 million year over year.
The company said losses declined to $5.3 million from $6.3 million in the year-ago period.
Sequenom said it had around $29.6 million in cash, cash equivalents, short-term investments, and restricted cash as of Sept. 30.
The company said it is increasing its 2006 financial guidance to $27 million from $24 million, which would be a 39-percent improvement over 2005.
Despite the positive results, shares in Sequenom were down 6.5 perecent, or $.23, at $3.30 in mid-afternoon trading today.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.